No Data
Guangzhou Wondfo Biotech (300482) 2024 Third Quarter Report Review: Steady Revenue Growth, Continuous Progress in Overseas Certification of Products
Subject: The company released the third quarter report of 24 years, 24Q1-3, with revenue of 2.181 billion yuan (+8.83%), net income attributable to the parent company of 0.436 billion yuan (+9.04%), and non-net profit of 0.388 billion yuan (+14%).
Guangzhou Wondfo Biotech (300482): rapid expansion of international business, strong resilience shown in domestic business.
Event: On October 25, the company released the third quarter report of 2024: The revenue for the first three quarters of 2024 was 2.181 billion yuan, an 8.83% year-on-year increase; net income attributable to the parent company was 0.436 billion yuan, a year-on-year increase
Express News | Guangzhou Wondfo Biotech's pathological products have received the first IVDR CE certification.
Wanfu Biotech: Report for the third quarter of 2024
guangzhou wondfo biotech (300482.SZ) released its performance for the first three quarters, with a net income of 0.436 billion yuan, an increase of 9.04%.
Guangzhou Wondfo Biotech (300482.SZ) released its third-quarter report for 2024, with the company's revenue for the first three quarters reaching 2...
Guangzhou Wondfo Biotech (300482): The performance growth in the third quarter accelerated compared to the previous quarter, bullish on full-year performance.
The company achieved revenue/net profit attributable to mother of 218.1/43.6 billion yuan in 1-3Q24 (yoy +8.8%/+9.0%), with revenue/net profit attributable to mother of 60.6/8.0 billion yuan in 3Q24
No Data
No Data